openPR Logo
Press release

Membranous Nephropathy Market Positioned for Accelerated Development Through 2032, DelveInsight Finds

08-21-2025 09:00 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Membranous Nephropathy Market Positioned for Accelerated

DelveInsight's "Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Membranous Nephropathy, historical and forecasted epidemiology as well as the Membranous Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Membranous Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Membranous Nephropathy Market Forecast
https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Membranous Nephropathy Market Report:
• The Membranous Nephropathy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In February 2025, Genentech, a subsidiary of Roche, has submitted positive Phase III data to the U.S. Food and Drug Administration (FDA) as it seeks to enter the lucrative lupus market with its CD20-targeting drug, Gazyva (obinutuzumab). Additionally, the company is investigating Gazyva for other autoimmune conditions, including systemic lupus erythematosus (SLE), childhood-onset idiopathic nephrotic syndrome, membranous nephropathy, and pediatric lupus nephritis.
• In 2023, idiopathic membranous nephropathy (IMN) accounted for about 80% of membranous nephropathy cases, while secondary cases comprised nearly 20% in the US.
• In 2023, the number of people in the United States with idiopathic membranous nephropathy was approximately 29,000.
• In the EU4 and the UK, PLA2R antigens were identified in about 18,000 IMN patients, while THSD7A antigens were found in around 1,000 patients.
• In a study conducted by Storrar et al. (2022), 178 patients with primary membranous nephropathy were monitored over two decades. The study found that 134 patients (75.3%) achieved remission, either spontaneously in 60 patients (33.7%) or after immunosuppressive treatment in 74 patients (41.6%). Among those in remission, 57 patients (42.5%) experienced a relapse. Additionally, 10.1% of the patients progressed to renal replacement therapy, and the mortality rate was 29.8%.
• According to a study by Alsharhan and Beck (2020), autoantibodies to PLA2R are believed to be the cause of primary membranous nephropathy (MN) in up to 80% of patients. Additionally, autoantibodies against THSD7A are responsible for 1-3% of MN cases in Western countries.
• Key Membranous Nephropathy Companies: argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others
• Key Membranous Nephropathy Therapies: efgartigimod IV, VB119, MOR202, MIL62, B007, SNP-ACTH (1-39) Gel, Zanubrutinib, Obinutuzumab, SHR1459, AP1189, povetacicept, WAL0921, Imlifidase, and others
• The Membranous Nephropathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Membranous Nephropathy pipeline products will significantly revolutionize the Membranous Nephropathy market dynamics.

Membranous Nephropathy Overview
Membranous Nephropathy is a chronic kidney disorder where the body's immune system attacks the membranes in the glomeruli - the tiny filtering units in the kidneys. This leads to thickening of the glomerular basement membrane, causing protein to leak into the urine (proteinuria). It is a common cause of nephrotic syndrome in adults. The condition can be primary (idiopathic) or secondary to other diseases like lupus, infections, cancer, or use of certain medications. Symptoms include swelling (especially in the legs), fatigue, and foamy urine. Treatment depends on the severity and underlying cause, ranging from observation to immunosuppressive therapy.

Get a Free sample for the Membranous Nephropathy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Membranous Nephropathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Membranous Nephropathy Epidemiology Segmentation:
The Membranous Nephropathy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Prevalent Cases of Membranous Nephropathy in the 7MM
• Prevalent Cases of Membranous Nephropathy by Types in the 7MM
• Prevalent Cases of Idiopathic Membranous Nephropathy by Antigens in the 7MM
• Treated Cases of Membranous Nephropathy in the 7MM

Download the report to understand which factors are driving Membranous Nephropathy epidemiology trends @ Membranous Nephropathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Membranous Nephropathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Membranous Nephropathy market or expected to get launched during the study period. The analysis covers Membranous Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Membranous Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Membranous Nephropathy Therapies and Key Companies
• GAZYVA (obinutuzumab): Hoffmann-La Roche
• MOR202 (felzartamab): MorphoSys/HI-Bio
• efgartigimod IV: argenx
• VB119: Tenet Medicines
• MOR202: Mario Negri Institute for Pharmacological
• MIL62: Beijing Mabworks Biotech
• B007: Shanghai Jiaolian Drug R&D
• SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
• Zanubrutinib: BeiGene
• Obinutuzumab: Hoffmann-La Roche
• SHR1459: Reistone Biopharma
• AP1189: SynAct Pharma
• povetacicept: Alpine Immune Sciences
• WAL0921: Walden Biosciences
• Imlifidase: Hansa Biopharma AB

Discover more about therapies set to grab major Membranous Nephropathy market share @ Membranous Nephropathy Treatment Landscape
https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Membranous Nephropathy Market Strengths
• The availability of assays for PLA2R antibodies has induced a dramatic change of the diagnostic strategy, owing to the very high specificity of anti-PLA2R antibody for the diagnosis of MN.
• With better efficacy results, and proteinuria reduction observed in six months after therapy, MOR202 (felzartamab) is expected to emerge as a strong therapeutic candidate and generate decent market share.

Membranous Nephropathy Market Opportunities
• Absence of marketed therapy in treatment space along with increasing patient pool paves the way for pharma players to come up with efficacious and cost effective treatment options
• High rate of progression and remission in patients with MN presents pharmaceutical companies with an opportunity to develop therapies to overcome the shortcomings and grab a highly untapped market.

Scope of the Membranous Nephropathy Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Membranous Nephropathy Companies: argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others
• Key Membranous Nephropathy Therapies: efgartigimod IV, VB119, MOR202, MIL62, B007, SNP-ACTH (1-39) Gel, Zanubrutinib, Obinutuzumab, SHR1459, AP1189, povetacicept, WAL0921, Imlifidase, and others
• Membranous Nephropathy Therapeutic Assessment: Membranous Nephropathy current marketed and Membranous Nephropathy emerging therapies
• Membranous Nephropathy Market Dynamics: Membranous Nephropathy market drivers and Membranous Nephropathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Membranous Nephropathy Unmet Needs, KOL's views, Analyst's views, Membranous Nephropathy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Membranous Nephropathy Market Positioned for Accelerated Development Through 2032, DelveInsight Finds here

News-ID: 4154906 • Views:

More Releases from DelveInsight Business Research

DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) Across 15 Countries
DelveInsight Unveils Comprehensive Epidemiology Assessment of Cutaneous Squamous …
DelveInsight, a global leader in healthcare research and analytics, announces the release of its in-depth Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology Assessment, providing unparalleled insights into the prevalence of cSCC among solid organ transplant recipients across 15 countries, including the United States, key European nations, and select countries in the Asia-Pacific (APAC) region. The newly released assessment delivers country-specific epidemiological insights aimed at guiding strategic decision-making for pharmaceutical companies, healthcare providers,
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (PFO) Device Landscape Analysis Empowers Strategic Market Entry in the EU
Unlocking Market Potential: DelveInsight's Comprehensive Patent Foramen Ovale (P …
DelveInsight's Market Size & Forecast Assessment Provides Data-Driven Insights for Patient-Centric Market Expansion Strategies DelveInsight, a leading healthcare market research and consulting firm, has released an in-depth case study highlighting its latest assessment of the Patent Foramen Ovale (PFO) Device Market across the European Union. This strategic market intelligence report provides a holistic understanding of the patient population, device market size, competitor landscape, and reimbursement scenario, equipping medical device companies with
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for Robust Growth at 6.35% CAGR through 2032, States DelveInsight
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market Poised for …
The Chronic Obstructive Pulmonary Disease (COPD) Treatment Devices Market is set for strong expansion, projected to grow at a CAGR of 6.35% from 2025 to 2032, according to recent industry findings. This growth is primarily fueled by the increasing global prevalence of COPD, escalating exposure to tobacco smoke and air pollution, expanding screening programs, and the rapid development of next-generation respiratory devices such as portable nebulizers and smart inhalers. The global
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market. The CD40 Pipeline report embraces in-depth commercial and

All 5 Releases


More Releases for Membranous

Membranous Nephropathy Market Positioned for Accelerated Development Through 203 …
DelveInsight's "Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Membranous Nephropathy, historical and forecasted epidemiology as well as the Membranous Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Membranous Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Membranous Nephropathy Market Forecast https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Idiopathic Membranous Nephropathy Market Size And Global Industry Forecast 2034
Introduction The Idiopathic Membranous Nephropathy (IMN) Market is experiencing steady growth as medical research advances understanding of this rare, immune-mediated kidney disorder. IMN, a leading cause of nephrotic syndrome in adults, is characterized by immune complex deposits on the glomerular basement membrane, leading to proteinuria and potential progression to kidney failure. Rising adoption of biomarker-driven diagnostics, targeted therapies, and increasing awareness in nephrology are expected to expand treatment adoption globally. Download Full
Membranous Nephropathy Market Forecasted for Consistent CAGR through 2024-2031
Membranous Nephropathy Market analysis, according to DataM Intelligence, offers more than just an overview; it investigates the underlying aspects of the sector. The study provides an overview, the research explores the hidden aspects of the sector, breaking down its intricate dynamics, charting regional dominance, spotting demand patterns, and spotting prospective breakthroughs that could influence how businesses operate in the future. Will the Membranous Nephropathy market emerge as the sector's next great
Membranous Nephropathy Market Forecast period 2022-2029.
The report is designed to provide a holistic view of the Membranous Nephropathy Market It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; revenue, demands, and supply data (as applicable). Regional estimates and forecasts & trend analysis for eac country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Luxemburg, Rest of Europe, Japan, China, South
Membranous Nephropathy Market Report Covers Future Trends with Research 2023-203 …
Market Research, INC. has recently published a report on Membranous Nephropathy market which is an essential tool for businesses to gather critical insights about their target markets, competitors, and industry trends. With the increasing complexity of the global business environment, companies need accurate and up-to-date information to make informed decisions and stay ahead of the competition. That's why we are excited to announce the release of our latest market research
Membranous Nephropathy Market Sets to Soar High with a CAGR | DelveInsight
"It is estimated that Membranous Nephropathy Treatment space will experience significant changes during the forecast period of 2022-2032, owing to the launch of novel therapies that are in clinical development for the management of Membranous Nephropathy Market" The Membranous Nephropathy market report provides current treatment practices, emerging drugs, Membranous Nephropathy market share of the individual therapies, current and forecasted Membranous Nephropathy market Size from 2019 to 2032 segmented by seven major